Previous Close | 52.21 |
Open | 52.33 |
Bid | 51.58 x 100 |
Ask | 54.68 x 100 |
Day's Range | 51.25 - 53.07 |
52 Week Range | 50.67 - 168.92 |
Volume | 609,519 |
Avg. Volume | 1,084,398 |
Market Cap | 2.827B |
Beta | 1.34 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Tesaro popped Monday after unveiling early data for a potential competitor to drugs from Dow Jones component Merck and Bristol.
Regeneron, Incyte and Tesaro have all had a terrible start to 2018, with shares down 14% or more.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. Over the last month, ETFs holding TSRO are favorable, with net inflows of $5.12 billion.
TESARO Inc at Raymond James Institutional Investors Conference
Management revealed data this week that could help the company against its competitors.
Analysts were split Tuesday on the results of a study combining drugs from Tesaro and Merck in ovarian cancer.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Eclipse Resources Corp (NYSE: ECR ) stock was trading ...
TESARO Inc NASDAQ/NGS:TSRO
Tesaro and Clovis Oncology hope to unseat the big pharma giant, but they've got their work cut out for them.
Q4 2017 TESARO Inc Earnings Call
CEO of Tesaro Inc (NASDAQ:TSRO) Leon O Jr Moulder bought 5,000 shares of TSRO on 03/02/2018 at an average price of $56.93 a share.
An In-Depth Look into AstraZeneca's 4Q17 Performance
Tesaro Inc (NASDAQ:TSRO) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Tesaro crashed to a two-year low Wednesday after its biggest moneymaker fell short in the fourth quarter.
A revenue miss suggests competitive pressure will be stronger than expected.
Investors in TESARO (TSRO) need to pay close attention to the stock based on moves in the options market lately.
Tesaro Inc. shares dropped 9.2% in premarket trade Wednesday after the company reported fourth-quarter earnings and revenue misses. Tesaro reported a loss of $186.1 million, or a loss of $3.35 per share, ...
Tesaro reported adjusted losses of $3.35 per share on $48 million in sales for the fourth quarter.
Exelixis and Clovis shares diverged Tuesday after each reported lackluster sales of their biggest cancer drugs in the fourth quarter.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. ETFs that hold TSRO had net inflows of $824 million over the last one-month.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. Over the last one-month, outflows of investor capital in ETFs holding TSRO totaled $15 million.
Regeneron, Alnylam, and Tesaro are all flailing, and these biotech stocks could continue to struggle in the near term.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. ETFs that hold TSRO had net inflows of $342 million over the last one-month.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. Over the last one-month, outflows of investor capital in ETFs holding TSRO totaled $246 million.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! BlackBerry Ltd (NYSE: BB ) gained nearly 5 percent ...